| Quarterly Financials | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
Revenue  | 1,764 | 2,200 | 2,457 | 2,130 | 2,103 | 2,642 | 2,772 | 2,682 | 2,517 | 2,976 | 3,173 | 3,286 | 3,333 | 3,653 | 3,791 | 3,643 | 3,560 | 4,080 |
| Expenses | 1,441 | 1,724 | 1,835 | 1,654 | 1,636 | 1,924 | 2,025 | 2,000 | 1,836 | 2,196 | 2,217 | 2,383 | 2,401 | 2,724 | 2,776 | 2,754 | 2,536 | 2,974 |
| EBITDA | 323 | 476 | 622 | 477 | 467 | 718 | 746 | 681 | 681 | 780 | 956 | 903 | 933 | 930 | 1,016 | 889 | 1,024 | 1,105 |
| Operating Profit % | 17 % | 21 % | 24 % | 21 % | 20 % | 25 % | 25 % | 23 % | 24 % | 23 % | 28 % | 26 % | 22 % | 24 % | 25 % | 23 % | 26 % | 26 % |
| Depreciation | 47 | 78 | 79 | 85 | 85 | 87 | 97 | 110 | 100 | 103 | 101 | 187 | 231 | 219 | 222 | 223 | 223 | 226 |
| Interest | 13 | 16 | 10 | 13 | 5 | 6 | 9 | 9 | 9 | 11 | 7 | 221 | 191 | 171 | 170 | 157 | 142 | 110 |
| Profit Before Tax | 263 | 382 | 533 | 379 | 377 | 625 | 641 | 562 | 572 | 666 | 849 | 495 | 511 | 541 | 624 | 509 | 659 | 770 |
| Tax | 70 | 84 | 110 | 83 | 84 | 130 | 130 | 103 | 95 | 123 | 190 | 111 | 86 | 96 | 104 | 95 | 100 | 195 |
| Net Profit | 193 | 298 | 423 | 296 | 294 | 494 | 511 | 460 | 477 | 543 | 659 | 385 | 425 | 445 | 520 | 414 | 559 | 574 |
| EPS in ₹ | 4.74 | 7.30 | 10.48 | 7.09 | 7.13 | 12.15 | 12.51 | 11.33 | 11.76 | 13.39 | 16.31 | 9.46 | 10.19 | 10.62 | 12.39 | 9.90 | 13.44 | 13.76 |
Mankind Pharma
Mankind Pharma
2,520.60
+85.00
(3.49%)
Market Cap
1,04,099.77 Cr
PE Ratio
48.73
Volume
7,11,803.00
Day High - Low
2,523.80 - 2,436.80
52W High-Low
2,642.00 - 1,909.70
There are new updates from the company20 hrs ago
View
Key Fundamentals
Market Cap
1,04,099.77 Cr
EPS
46.35
PE Ratio
48.73
PB Ratio
6.18
Book Value
394.64
EBITDA
3,976.20
Dividend Yield
0.04 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
11.70
Debt to Equity
0.48
Analyst Rating and Forecast
- By Refinitiv from19 analysts
Actual
Company News
View All News
S.R. Batliboi & Co. LLP resigned as statutory auditors of Bharat Serums and Vaccines Ltd, a material subsidiary of Mankind Pharma, following voluntary liquidation proceedings initiated in September 2026.
Mankind Pharma shareholders approved the appointment of Anish Vanraj Bafna as an independent director via postal ballot. The resolution passed with 99.96% support, with promoters casting all votes in favor.
Mankind Pharma gets ESG rating of 68.21 for FY26Sep 15, 2026
Mankind Pharma has received an ESG rating of 68.21 from Niche99, placing it in the Leader category for FY26, reflecting its sustainability performance assessment.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,847.30 | #1 4,43,229.15 | 36.44 | #1 61,673.90 | 12.69 | #1 11,565 | 26.53 | 40.74 | |
9,566.50 | 2,53,960.52 | 86.51 | 11,067.00 | 13.95 | 2,568 | 65.50 | 63.87 | |
4,865.00 | 1,85,048.96 | 85.91 | 13,886.20 | 20.34 | 2,138 | 3.28 | 46.50 | |
1,212.00 | 1,21,955.56 | 26.32 | 27,657.90 | 17.64 | 5,026 | -34.90 | 66.57 | |
1,386.90 | 1,12,040.07 | 33.44 | 29,044.60 | 2.24 | 3,870 | -39.18 | 45.42 | |
2,015.10 | 1,08,786.50 | 99.70 | 6,867.80 | 22.01 | 890 | #1 123.93 | 64.04 | |
2,520.60 | #7 1,04,099.77 | #7 48.73 | #7 14,636.40 | #5 14.85 | #9 1,938 | #3 29.13 | 55.24 | |
1,243.60 | 1,03,799.45 | 32.05 | 35,058.60 | 3.90 | 4,158 | -69.10 | 63.11 | |
1,706.50 | 98,188.24 | 26.36 | 34,145.20 | 5.56 | 3,503 | 25.21 | 54.66 | |
2,071.20 | 94,702.00 | #1 16.99 | 29,038.90 | #1 26.75 | 5,356 | 16.00 | 35.30 |
Growth Rate
Revenue Growth
14.85 %
Net Income Growth
-3.41 %
Cash Flow Change
29.33 %
ROE
-15.03 %
ROCE
3.38 %
EBITDA Margin (Avg.)
-2.58 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 6,373 | 9,148 | 9,715 | 11,963 | 27,760 | 28,080 |
| Fixed Assets | 1,664 | 3,588 | 4,251 | 4,545 | 19,005 | 18,621 |
| Current Assets | 3,907 | 4,407 | 4,328 | 6,568 | 6,988 | 6,954 |
| Capital Work in Progress | 372 | 702 | 550 | 282 | 826 | 1,128 |
| Investments | 1,512 | 1,110 | 1,346 | 2,568 | 2,042 | 1,985 |
| Other Assets | 2,824 | 3,749 | 3,568 | 4,568 | 5,887 | 6,346 |
| Total Equity & Liabilities | 6,373 | 9,148 | 9,715 | 11,963 | 27,760 | 28,080 |
| Current Liabilities | 1,353 | 2,624 | 1,863 | 2,120 | 5,664 | 6,507 |
| Non Current Liabilities | 156 | 208 | 229 | 268 | 7,528 | 5,011 |
| Total Equity | 4,863 | 6,316 | 7,623 | 9,576 | 14,568 | 16,561 |
| Reserve & Surplus | 4,682 | 6,115 | 7,395 | 9,323 | 14,291 | 16,259 |
| Share Capital | 40 | 40 | 40 | 40 | 41 | 41 |
Cash Flow
| Cash Flow | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Net Cash Flow | 103 | -92 | 156 | 22 | 77 | 22 | -12 |
| Investing Activities | -436 | -1,222 | -1,369 | -1,052 | -2,081 | -12,624 | -181 |
| Operating Activities | 1,070 | 1,137 | 920 | 1,813 | 2,152 | 2,413 | 3,121 |
| Financing Activities | -531 | -8 | 605 | -740 | 5 | 10,233 | -2,953 |
Share Holding
| % Holding | Sept 2022 | Mar 2023 | May 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| Promoter | 79.00 % | 76.50 % | 76.50 % | 76.50 % | 76.50 % | 76.50 % | 74.88 % | 74.87 % | 74.87 % | 72.71 % | 72.70 % | 72.68 % | 72.67 % | 72.66 % | 72.66 % | 72.63 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 9.87 % | 11.58 % | 12.37 % | 13.34 % | 12.92 % | 13.07 % | 12.84 % | 11.34 % | 10.24 % | 9.45 % |
| DIIs | 0.00 % | 2.64 % | 2.64 % | 4.64 % | 4.39 % | 9.49 % | 11.14 % | 9.95 % | 9.90 % | 11.06 % | 11.48 % | 11.50 % | 11.92 % | 13.25 % | 14.46 % | 15.39 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 4.15 % | 4.15 % | 1.02 % | 1.11 % | 1.14 % | 1.22 % | 1.46 % | 1.55 % | 1.60 % | 1.64 % | 1.52 % | 1.36 % | 1.52 % | 1.39 % | 1.29 % |
| Others | 21.00 % | 16.71 % | 16.71 % | 17.83 % | 18.00 % | 12.87 % | 2.89 % | 2.15 % | 1.31 % | 1.30 % | 1.26 % | 1.23 % | 1.21 % | 1.23 % | 1.25 % | 1.24 % |
| No of Share Holders | 17 | 4,02,322 | 4,02,322 | 1,31,918 | 1,34,731 | 1,27,449 | 1,35,116 | 1,53,450 | 1,63,854 | 1,72,431 | 1,80,597 | 1,79,549 | 1,70,347 | 1,77,539 | 1,77,606 | 1,66,715 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 09 Aug 2024 |  Annual General Meeting | NA | 09 Aug 2024 | 2,114.50 | 2,068.60 |
| 05 Nov 2024 |  Quarterly Result Announcement | NA | 05 Nov 2024 | 2,504.25 | 2,734.95 |
| 23 Jan 2025 | Quarterly Result Announcement | NA | 23 Jan 2025 | 2,738.25 | 2,515.05 |
| 21 May 2025 | Quarterly Result Announcement | NA | 21 May 2025 | 2,432.40 | 2,550.70 |
| 31 Jul 2025 | Quarterly Result Announcement | NA | 31 Jul 2025 | 2,578.00 | 2,575.50 |
| 07 Aug 2025 | Annual General Meeting | NA | 07 Aug 2025 | 2,384.70 | 2,553.25 |
| 08 Aug 2025 |  Dividend | ₹ 1.00 /share | 08 Aug 2025 | 2,575.50 | 2,537.80 |
| 06 Nov 2025 | Quarterly Result Announcement | NA | 06 Nov 2025 | 2,432.40 | 2,369.35 |
| 03 Feb 2026 | Quarterly Result Announcement | NA | 03 Feb 2026 | 2,261.20 | 2,063.80 |
| 19 May 2026 | Quarterly Result Announcement | NA | 19 May 2026 | 2,361.90 | 2,496.35 |
| 30 Jul 2026 | Quarterly Result Announcement | NA | 30 Jul 2026 | 2,546.60 | 2,592.55 |
| 04 Aug 2026 | Annual General Meeting | NA | 04 Aug 2026 | 2,485.30 | 2,483.00 |
Announcements
Resignation Of Statutory Auditors Of A Material WOS
20 hrs ago
20 hrs agoClosure of Trading Window3 days ago
3 days ago Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportSep 17, 2026
Sep 17, 2026Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotSep 17, 2026
Sep 17, 2026Intimation Regarding ESG RatingSep 15, 2026
Sep 15, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 11, 2026
Sep 11, 2026Update On Voluntary Liquidation Of WOSSep 07, 2026
Sep 07, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSSep 01, 2026
Sep 01, 2026Update On DisinvestmentAug 31, 2026
Aug 31, 2026Announcement under Regulation 30 (LODR)-Change in ManagementAug 30, 2026
Aug 30, 2026Announcement under Regulation 30 (LODR)-RestructuringAug 26, 2026
Aug 26, 2026Board Meeting Outcome for Dated August 26 2026Aug 26, 2026
Aug 26, 2026Intimation Regarding ESG RatingAug 22, 2026
Aug 22, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 20, 2026
Aug 20, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 19, 2026
Aug 19, 2026Shareholder Meeting / Postal Ballot-Notice of Postal BallotAug 18, 2026
Aug 18, 2026Completion Of Realignment Of Security Cover In Respect Of Non-Convertible Debentures And Consequent Release Of Pledged Shares Of Bharat Serums And Vaccines LimitedAug 17, 2026
Aug 17, 2026Announcement under Regulation 30 (LODR)-Updates on AcquisitionAug 13, 2026
Aug 13, 2026Announcement under Regulation 30 (LODR)-Change in ManagementAug 10, 2026
Aug 10, 2026Announcement under Regulation 30 (LODR)-Change in ManagementAug 10, 2026
Aug 10, 2026Board Meeting Outcome for For Appointment Of An Additional Director Designated As Non-Executive Independent DirectorAug 10, 2026
Aug 10, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 10, 2026
Aug 10, 2026Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 06, 2026
Aug 06, 2026Shareholder Meeting / Postal Ballot-Outcome of AGMAug 04, 2026
Aug 04, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 04, 2026
Aug 04, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 31, 2026
Jul 31, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 30, 2026
Jul 30, 2026Compliances-Reg. 54 - Asset Cover details Jul 30, 2026
Jul 30, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 30, 2026
Jul 30, 2026Announcement under Regulation 30 (LODR)-Investor PresentationJul 30, 2026
Jul 30, 2026Approval For Issuance Of Corporate GuaranteeJul 30, 2026
Jul 30, 2026Un-Audited Financial Results Of The Company For The Quarter Ended On June 30 2026Jul 30, 2026
Jul 30, 2026Board Meeting Outcome for Outcome Of Board MeetingJul 30, 2026
Jul 30, 2026Final Update On Stake Sale Of Broadway Hospitality Services Private LimitedJul 27, 2026
Jul 27, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 17, 2026
Jul 17, 2026Board Meeting Intimation for Approval Of Financial ResultsJul 16, 2026
Jul 16, 2026Announcement under Regulation 30 (LODR)-Diversification / DisinvestmentJul 11, 2026
Jul 11, 2026Announcement under Regulation 30 (LODR)-AcquisitionJul 11, 2026
Jul 11, 2026Board Meeting Outcome for Outcome Of Board MeetingJul 11, 2026
Jul 11, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 10, 2026
Jul 10, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 10, 2026
Jul 10, 2026Business Responsibility and Sustainability Reporting (BRSR)Jul 09, 2026
Jul 09, 2026Regulation 53 (1) Annual Report.Jul 09, 2026
Jul 09, 2026Reg. 34 (1) Annual Report.Jul 09, 2026
Jul 09, 2026Notice Of 35Th AGMJul 09, 2026
Jul 09, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 01, 2026
Jul 01, 2026Intimation Of Date Of AGMJun 30, 2026
Jun 30, 2026Closure of Trading WindowJun 25, 2026
Jun 25, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 15, 2026
Jun 15, 2026Announcement under Regulation 30 (LODR)-Change in ManagementJun 08, 2026
Jun 08, 2026Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 55.24
ATR(14)
Volatile 56.64
STOCH(9,6)
Overbought 90.11
STOCH RSI(14)
Overbought 88.13
MACD(12,26)
Bullish 23.43
ADX(14)
Weak Trend 24.68
UO(9)
Bearish 59.31
ROC(12)
Uptrend And Accelerating 7.53
WillR(14)
Neutral -24.42
About Mankind Pharma
Mankind Pharma Limited is an Indian pharmaceutical company incorporated in 1991. It develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products. The company operates in various therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. Mankind Pharma entered the consumer healthcare segment in 2007 and has since...more
Listing Date
09 May, 2023(3 Years, 4 Months, 20 Days)
Chairperson NameRAMESH CHAND JUNEJA
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
